Overview

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
0
Participant gender:
All
Summary
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
ALX Oncology Inc.
Collaborator:
Eli Lilly and Company
Treatments:
Paclitaxel
Ramucirumab
Trastuzumab
Criteria
Inclusion Criteria:

- HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ)
adenocarcinoma that has progressed on or after a prior HER2-directed agent and
fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

- Adequate Bone Marrow Function.

- Adequate Renal & Liver Function.

- Adequate Performance Status

Exclusion Criteria:

- Patients with known symptomatic CNS metastases or leptomeningeal disease requiring
steroids.

- Prior treatment with any anti-CD47 or anti-SIRPĪ± agent.

- Prior treatment with ramucirumab.